← Eichor
Study identifier: NCT06073626 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Addressing Genomic Disparities in Cancer Survivors

Condition: Hereditary Cancer · Genetic Testing  ·  Sponsor: Rutgers, The State University of New Jersey

PhaseNA
Planned participants428
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing. 2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). 3. Explore the ways (methods) that influence how participants experience the intervention. 4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA. The main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which m…

This description comes directly from the study's public registry record.

Talk to the study team

Erin Speiser, PhD, MA  ·  732-675-1668  ·  erin.speiser@rutgers.edu

Julie Chapman Greene, PhD, MPH  ·  chapmaje@cinj.rutgers.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Georgetown Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia, United StatesRecruiting
Rutgers Cancer InstituteNew Brunswick, New Jersey, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06073626